Latest news with #moleculardiagnostics
Associated Press
3 days ago
- Business
- Associated Press
Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.
SALT LAKE CITY, Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the 'Company' or 'Co-Dx'), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will be hosting a booth at the 17th Annual Next Generation Dx Summit, held virtually and in-person at the Capital Hilton in Washington, D.C. on August 18-20, 2025. Cambridge Healthtech Institute's Next Generation Dx Summit is described as the nexus for international thought leaders to network and discuss diagnostic advancement and technology innovation, and offers a valuable window into how point-of-care, decentralized testing, infectious disease, liquid biopsy and companion diagnostics are improving the standard of care in the diagnostics industry. Attendees are invited to visit the Company at Booth #12 to learn more about the Co-Dx Logix Smart® suite of clinical laboratory solutions, as well as the upcoming Co-Dx PCR diagnostics platform* and the pipeline of upper respiratory, tuberculosis and HPV tests, all of which the Company is anticipating entering into clinical evaluations during 2025. To learn more about the summit, including in-person and virtual registration details, please visit Company travel and conference attendance is made possible due in part to a grant from World Trade Center Utah, a member of the World Trade Centers Association founded in 2006 with the goal of helping Utah companies increase revenue and create jobs by expanding international sales, attracting foreign investment, and facilitating international partnerships. *The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease. View original content to download multimedia: SOURCE Co-Diagnostics
Yahoo
3 days ago
- Business
- Yahoo
Press Release Biocartis NV: Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development
PRESS RELEASE - 08/18/2025, 09:00 AM EDT Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development Itasca (IL), United States, August 18th, 2025 – Biocartis Group of Companies ('Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Mike Kreitzinger as Senior Vice President (SVP) of Global Business Development, effective 18 August 2025. Mr. Kreitzinger and his team will focus on sourcing and executing partnership opportunities and forging alliances to drive commercial growth and expand the global integration of Biocartis solutions into the precision oncology ecosystem. With a career spanning more than 25 years in clinical diagnostics, Mr. Kreitzinger brings a unique blend of business strategy, clinical diagnostic sales, and commercial leadership expertise to Biocartis. Most recently, he served as Senior Director of Clinical Strategy and Partnerships at Illumina, where he led the development and implementation of comprehensive strategic clinical plans to bring next-generation sequencing closer to the patient and aligned partnerships to accelerate adoption of genomics in the clinic. Prior to that, Mr. Kreitzinger held various senior commercial leadership roles at Illumina and led US sales at other companies, including Cepheid (a Danaher company) and Alere, now part of Abbott Diagnostics. Mr. Kreitzinger holds an MBA from Florida Gulf Coast University and Bachelor of Arts degree from Florida State University. "I am honored to join the stellar team at Biocartis as we advance the mission of providing rapid oncology biomarker results. Cancer is a disease of the genome, and rapid assessment enables providers the answers they need…when they need them," said Mike Kreitzinger, Senior Vice President of Global Business Development. "I am joining Biocartis to help shape the future of cancer care and look forward to establishing partnerships to bring ultra-fast biomarker testing closer to patients and their physicians.' ----- END ----- More information: Biocartis NV. Generaal De Wittelaan 11B, 2800 Mechelen, Belgium Biocartis US Inc. 2 Pierce Place, Suite 1510, Itasca, IL 60143, US | info@ About Biocartis Biocartis is committed to helping cancer patients worldwide access the right treatment faster. With our proprietary Idylla™ Platform, we deliver in-house molecular biomarker results in only 3 hours, enabling healthcare professionals to make timely, informed decisions that guide personalized therapy. Our expanding portfolio of diagnostic tests and research assays addresses key unmet clinical needs across multiple cancers, including lung, skin, thyroid, colorectal, endometrial, blood, brain, and breast cancer. Learn more at and follow us on LinkedIn, Facebook and X (Twitter). Disclaimers Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis NV. © August 2025, Biocartis NV. All rights reserved.
Yahoo
24-07-2025
- Business
- Yahoo
Exagen Inc. (XGN): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish thesis on Exagen Inc. on by inflection99. In this article, we will summarize the bulls' thesis on XGN. Exagen Inc.'s share was trading at $7.00 as of July 16th. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. Exagen (XGN) is a molecular diagnostics company specializing in autoimmune diseases like lupus and rheumatoid arthritis, primarily serving rheumatologists with its proprietary AVISE® test suite. Its flagship product, AVISE CTD, offers superior diagnostic capabilities versus the standard of care, combining multiple tests with enhanced sensitivity and specificity, reducing diagnosis time, hospitalizations, and repeat testing. The autoimmune diagnostics market is large, underserved, and economically attractive to all stakeholders—patients, providers, and payers—due to better outcomes, cost savings, and improved practice efficiency. This favorable market backdrop is amplified by the emergence of novel lupus therapies, increasing pharma's incentive to partner with diagnostics players like Exagen. The company holds key advantages through its proprietary biomarkers, unique reimbursement code, and growing coverage with Medicare and commercial payers. Recent innovations, such as new T-cell markers and early kidney disease detection, support pricing power, gross margin expansion, and potential biopharma revenue. Led by CEO John Aballi—who previously executed a similar playbook at Decipher before selling to Veracyte—Exagen has transformed from a cash-burning operation to near breakeven, with revenue acceleration, ASP tailwinds, and profitability expected by Q4 2025. Strategic interest is also plausible; Labcorp recently highlighted autoimmune disease as a priority area, positioning Exagen as a potential acquisition target. With minimal sell-side coverage, recent capital raises, and multiple upcoming catalysts—including improved reimbursement, guideline inclusion, and biopharma partnerships—Exagen is poised for a re-rating. Applying a conservative 4.5x 2026E revenue multiple implies 2.5–3x upside from current levels, while downside appears limited given the business's turnaround, strategic value, and current low-end peer valuation. Previously, we covered a bullish thesis on Oscar Health, Inc. (OSCR) by Oguz Erkan in May 2025, which highlighted the company's tech-driven platform, margin improvement, and expansion opportunity in ACA markets. The company's stock price has appreciated by approximately 21.62% since our coverage. This is because the thesis played out. Inflection99 shares a similar view on Exagen but emphasizes its autoimmune diagnostics advantage. Exagen Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held XGN at the end of the first quarter which was 7 in the previous quarter. While we acknowledge the potential of XGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-07-2025
- Business
- Yahoo
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-07-2025
- Business
- Yahoo
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
